Source comparison
Tesamorelin vs Exogenous Growth Hormone
The distinction matters clinically. Exogenous GH (somatropin) delivers a fixed dose that bypasses the pituitary entirely. This often raises IGF-1 levels above the physiological range, increasing the risk of edema, joint pain, carpal tunnel syndrome, and insuli
This comparison does not assign a generated winner or score.
- The distinction matters clinically. Exogenous GH (somatropin) delivers a fixed dose that bypasses the pituitary entirely. This often raises IGF-1 levels above the physiological range, increasing the risk of edema, joint pain, carpal tunnel syndrome, and insulin resistance.
- Tesamorelin stimulates endogenous GH release, which means the pituitary retains its negative feedback loop. When GH and IGF-1 rise, somatostatin signals the pituitary to slow down. This self-regulating mechanism keeps levels closer to the physiological ceiling (Dhillon, Drugs 2011).
- Mechanism
- Direct GH replacement
- Stimulates pituitary GH release
- GH pattern
- Flat, supraphysiological spike
- Pulsatile, physiological
- Feedback loop
- Suppressed
- Preserved
- IGF-1 elevation
- Often supraphysiological
- Usually within range
- Insulin resistance risk
- Higher
- Lower
- Joint pain/edema
- Common at therapeutic doses
- Less common
- For researchers comparing growth hormone secretagogues, our peptide stacking guide covers how tesamorelin fits alongside other GH peptides.